SCHEMBL3864685

SCHEMBL3864685

C#CCOc1nc(Nc2cc(N)c(C)c(C(=O)O)c2)ncc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 3/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
ULK2 Q8IYT8 1/20 0.40
CDK1 P06493 8/20 0.38
CDK2 P24941 8/20 0.38
KDR P35968 6/20 0.38
CCNB1 P14635 4/20 0.38
CCNE1 P24864 3/20 0.38
MAPK8 P45983 2/20 0.36
CA2 P00918 1/20 0.36
EGFR P00533 2/20 0.36
ITK Q08881 1/20 0.36
AURKA O14965 1/20 0.35
CHEK1 O14757 1/20 0.35
NTRK2 Q16620 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3864684 0.81 CDK1 (0.41) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL3865631 0.81 CDK1 (0.35) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL3864679 0.77 ULK1 (0.39) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL3867438 0.74 CDK1 (0.38) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL13897842 0.74 TOP2A (0.39) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL4023231 0.74 CDK2 (0.49) CDK1CDK2KDRCCNB1CCNE1
SCHEMBL13897693 0.73 CDK1 (0.46) CDK1CDK2KDRCCNB1CCNE1
SCHEMBL6451895 0.73 CDK2 (0.48) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL3866210 0.73 RAB9A (0.52) CDK1CDK2KDRCCNB1CCNE1
SCHEMBL13897482 0.73 SYK (0.49) PRKAA1CDK1CDK2KDRCCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
EP-1565446-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-24 EP disclosed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 US disclosed
WO-2004048343-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK ULK1 62/4885PRKAA2 265/4885PRKAA1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.